Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_95619

Ice-bucket challenge funds ALS gene discoveries

1 August 2016
Appeared in BioNews 862

Donations from the ALS, amyotrophic lateral sclerosis, 'ice-bucket challenge' have funded research that has led to the discovery of new genes linked to the disease.

The ice-bucket challenge – in which people had buckets of iced water poured over their heads to raise money for charity – went viral on social media in the summer of 2014. Donations allowed the ALS Association to invest $1 million in Project MinE, a large-scale sequencing project that involved 11 countries and 80 researchers. It aims to identify all the genetic causes of ALS by mapping the genomes of at least 15,000 people with the disease. Two studies from the project, both published in Nature Genetics, have identified two new genes involved in ALS. 

Professor Ammar Al-Chalabi, one of the leading researchers working on Project MinE, said: 'By working together, ALS researchers across the world, patients and the public have successfully driven the discovery of these new ALS genes.'

ALS (also known as motor neurone disease) is a progressive neurological disorder in which the motor neurons that control muscle function degenerate and eventually die. Approximately 10 percent of ALS cases are inherited, but scientists believe that genetics contribute either directly or indirectly to a much larger percentage of cases.

The first study was a genome-wide association study and found a total of six genetic regions where variation appears to increase the risk of ALS. One of the regions included a novel gene called C21orf2, which plays a role in cilia formation and mitochondrial function.

The second study found that mutations in the NEK1 gene increased the risk of ALS. NEK1 is known to play multiple roles in neuron function, including DNA repair, mitochondrial membrane permeability and regulation of the cytoskeleton of nerve cells.

Although only associated with three percent of ALS cases, NEK1 was implicated in both sporadic and inherited forms of the disease, meaning it could be a new target for the development of possible treatments.

'The discovery of NEK1 highlights the value of big data in ALS research,' said Dr Lucie Bruijn, chief scientist at the ALS Association, who was not involved in the studies. 'The sophisticated gene analysis that led to this finding was only possible because of the large number of ALS samples available. The ALS ice-bucket challenge enabled [us] to invest in Project MinE's work to create large biorepositories of ALS biosamples that are designed to allow exactly this kind of research and to produce exactly this kind of result.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE
5 October 2015 - by Hannah Somers 
Reactivation of an ancient virus embedded in the human genome may trigger the onset of motor neurone disease...
13 October 2014 - by Rhys Baker 
The US Food and Drug Administration (FDA) has awarded 'fast-track' status to a potential stem cell therapy for Amyotrophic Lateral Sclerosis (ALS), or motor neurone disease...
22 April 2013 - by Matthew Young 
A neural stem cell therapy aimed at treating the symptoms of amyotrophic lateral sclerosis (ALS) is set to advance in the USA, after the Food and Drug Administration (FDA) gave its approval for it to proceed to the next stage of clinical trials...
2 April 2012 - by Dr Linda Wijlaars 
A clinical trial to test the safety of a stem cell treatment for amyotrophic lateral sclerosis, the most common form of motor neurone disease, suggests that the new therapy is safe and well-tolerated. Encouragingly, one of the 12 patients participating in the study showed some improvement, although the trial was not designed to test the treatment's efficacy...
26 September 2011 - by George Frodsham 
Researchers have identified a strong link between a genetic fault and two common neurological disorders. Two independent studies have found that the mutation is common in patients with amyotrophic lateral sclerosis (ALS) and patients with frontotemporal dementia (FTD), particularly if the disease is familial...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.